ANI Pharma (NASDAQ: ANIP) reported Q2 EPS of $0.98, $0.11 better than the analyst estimate of $0.87. Revenue for the quarter came in at $44.8 million versus the consensus estimate of $43.7 million.

ANI Reaffirms Guidance for the Full Year 2017

ANI\'s estimates are based on projected results for the twelve months ending December 31, 2017 and reflect management\'s current beliefs about product pricing, prescription trends, inventory levels, cost of sales, operating costs, taxes, and the anticipated timing of future product launches and events.

• Net revenues for 2017 to be between $181 million and $190 million.
• Cost of sales as a percent of revenues, excluding impact of inventory step-up, to be between 42% and 44%.
• Adjusted non-GAAP EBITDA to be between $73.1 million and $77.2 million.
• Adjusted non-GAAP diluted earnings per share to be between $3.58 and $3.94.

GUIDANCE:

ANI Pharma sees FY2017 EPS of $3.58-$3.94, versus the consensus of $3.79. ANI Pharma sees FY2017 revenue of $181-190 million, versus the consensus of $182.55 million.

For the second quarter 2017:

• Net revenues of $44.8 million, an increase of 43% as compared to the same period in 2016
• GAAP net income of $2.7 million and diluted GAAP earnings per share of $0.23
• Adjusted non-GAAP EBITDA of $19.1 million
• Adjusted non-GAAP diluted earnings per share of $0.98

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.